The mechanism by which paclitaxel increases the number of peripheral NK cells is not known, although prior administration of paclitaxel is thought to up-regulate Tmab-mediated ADCC in the presence of αCD137 mAb against HER2-low-expressing human pancreatic cancer. Here, ERBB2 is linked to familial pancreatic carcinoma.